- Home
- ESLA vs BEAT Comparison
ESLA vs BEAT Comparison
Compare ESLA & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESLA | BEAT |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 31.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ESLA | BEAT |
|---|---|---|
| Price | $0.77 | $0.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $8.00 | $5.63 |
| AVG Volume (30 Days) | 45.3K | ★ 639.8K |
| Earning Date | 05-26-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $315.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.50 |
| 52 Week High | $3.15 | $4.00 |
Technical Indicators
Market Signals| Indicator | ESLA | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 34.69 | 35.97 |
| Support Level | $0.73 | $0.52 |
| Resistance Level | $1.28 | $0.79 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 6.70 | 12.95 |
Price Performance
Historical ComparisonAbout ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.